National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Waldenström's Macroglobulinemia is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
Related Disorders List
Information on the following diseases can be found in the Related Disorders section of this report:
Waldenström's macroglobulinemia (WMG) is a malignant disorder of the blood, a type of lymphoma and characterized by the presence of abnormally large numbers of a particular kind of white blood cell known as B lymphocytes. As these cells accumulate in the body, excessive quantities of an antibody known as IgM are produced. Large amounts of IgM causes the blood to become thick (hyperviscosity) and affects the flow of blood through the smaller blood vessels, leading to the symptoms of the disorder. The organs fed by these small blood vessels do not receive sufficient blood and oxygen, potentially resulting in partial or complete failure of the organ.
Symptoms of Waldenström's macroglobulinemia usually begin gradually. Common symptoms are fatigue and loss of energy due to anemia. Bleeding from the nose and gums may also occur, and tingling in the fingers and toes is often seen (peripheral neuropathy). Examination may also reveal enlarged liver, spleen, or lymph nodes. Blurring or vision impairment may also occur due to changes in blood flow through the blood vessels that serve the retina. The symptoms are quite variable depending on the effect of the thickened (viscous) blood on the organ involved.
The causes of Waldenström's macroglobulinemia are unknown. There is evidence of occurrence within families, but such occurrence is uncommon.
Waldenström's macroglobulinemia is a very rare disorder affecting about 1 in 3.4 million American men and about half that number of American women. The incidence of WMG is estimated to be about 5 per 1,000,000 people over the age of 50. The median age at diagnosis is 63. However, cases have been diagnosed in patients in their twenties. This disorder is considerably less common among people of African descent.
The disease is classified as a subset of lymphocytic lymphoma and also has characteristics in common with chronic lymphocytic leukemia and multiple myeloma.
Multiple myeloma is characterized by excessive growth (neoplastic proliferation) of plasma cells. Plasma cells are produced in the marrow and eventually enter the blood stream. They are a key component of the immune system and secrete a substance known as M-protein, a type of antibody. Antibodies, also known as immunoglobulins, are produced by the body to combat invading microorganisms, toxins, or other foreign substances. Overproduction of plasma cells in affected individuals results in abnormally high levels of these proteins in the body. In addition, excessive plasma cells may eventually mass together to form a tumor, known as a plasmacytoma, in various sites of the body, especially the bone marrow.
Chronic lymphocytic leukemia is the most common type of leukemia in people over 50 years of age. It is characterized by fatigue, weight loss, repeated infections and enlarged lymph nodes. Small, well-separated, movable, hard nodes usually occur. The number of lymph cells in the peripheral blood and bone marrow is chronically elevated. In the advanced stages of the disease, bone marrow failure is common, resulting in an abnormally low red blood cell count (anemia) and lack of blood platelets (thrombocytopenia).
When patients show symptoms of an enlarged spleen and liver combined with bleeding of the retina, WMG is reasonably suspected. The results of a complete blood count (CBC) usually show low red blood cell counts as well as low platelet counts. In such circumstances, electrophoresis (subjecting blood plasma to an electric impulse) of serum samples will show a peak reading for IgM.
With asymptomatic patients, a period of watchful waiting is considered the preferred course. To reduce the blood thickness, plasmapheresis, a method of blood exchange which filters out much of the IgM protein, has been shown to be effective in delaying the need for more aggressive treatment. The blood cells are separated from the liquid component (serum or plasma). The heavy IgM molecules that cause the trouble are discarded with the liquid fraction of the exchange. The red blood cells are "reconstituted" by adding previously donated plasma or a plasma substitute. If the disorder progresses, red blood cell transfusions and/or white blood cell transfusions and/or platelet infusions may be necessary.
Traditional chemotherapeutic agents, particularly chlorambucil (Leukeran), cyclophosphamide (Cytoxan), and/or melphalan (Alkeran) either as single agents or in combination with others, have been used in the management of this disease for over 40 years. The monoclonal antibody, rituximab, has been found to be effective. Ongoing research is examining combinations of these drugs. Many new therapies have been introduced in the past few years and include fludarabine, cladribine, bortezomib,lenalidomide, bendamustine and everolimus.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
A search of the Clinical Trials database maintained by the National Institutes of Health at www.clinicaltrials.gov yields 55 trials for WMG.
Peripheral blood stem transplant and bone marrow transplant, using the patient's own stem cells or marrow and that of related or unrelated donors, has been used but the procedure remains highly controversial.
Kipps TJ. Macroglobulinemia. In Lichtman MA, Beutler E, Kipps TJ, Selisohn U, et al. eds. Williams Hematology. 7th ed. New York, NY: McGraw-Hill Companies; 2006:1549-60.
Longo DL, Anderson KC. Plasma cell disorders. In: Kasper, DL, Fauci AS, Longo DL, et al. Eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill Companies; 2005:656, 661.
Gertz MA. Waldenström Macroglobulinemia. In: NORD Guide to Rare Disorders. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:37-38.
Berkow R., ed. The Merck Manual-Home Edition.2nd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2003:1009-1010.
Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:964-65.
Gertz MA. Waldenström macroglobulinemia: a review of therapy. Am J Hematol. 2005;79(2):147-57.
Lin P, Medeiros LJ. Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: an eveolving concept. Adv Anat Pathol. 2005;12:246-55.
Robak T, Korycka A, Kasznicki M, et al. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets. 2005;5:421-44.
Dimopoulos MA, Anagnostopoulos A. Waldenström's macroglobulinemia. Best Pract Res Clin Haematol. 2005;18:689-707.
Gertz MA. Waldenström macroglobulinemia: a review of therapy. Am J Hematol. 2005;79:147-57.
Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenström's macroglobulinemia. .J Clin Oncol. 2005;23:1564-77.
Bjorkholm M. Treatment options for Waldenström's macroglobulinemia. Clin Lymphoma. 2005;5:155-62.
American Cancer Society. Waldenström Macroglobulinemia. http://documents.cancer.org/acs/groups/cid/documents/webcontent/003148-pdf.pdf. Last Updated January 31, 2012. Accessed March 20, 2012.
Macroglobulinemia of Waldenström. Medical Encyclopedia. Medline Plus. http://www.nlm.nih.gov/medlineplus/ency/article/000588.htm. Updated April 30, 2010. Accessed March 20, 2012./
National Cancer Institute. Waldenström Macroglobulinemia: Questions and Answers..
www.cancer.gov/cancertopics/factsheet/Sites-Types/WM. Updated September 25, 2007. Accessed March 20, 2012.
American Cancer Society, Inc.
250 Williams NW St
Atlanta, GA 30303
NIH/National Heart, Lung and Blood Institute
P.O. Box 30105
Bethesda, MD 20892-0105
National Cancer Institute
6116 Executive Blvd Suite 300
Bethesda, MD 20892-8322
International Waldenstrom's Macroglobulinemia Foundation
6144 Clark Center Ave.
Sarasota, FL 34238
Rare Cancer Alliance
1649 North Pacana Way
Green Valley, AZ 85614
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126
Gaithersburg, MD 20898-8126
PO Box 241956
Los Angeles, CA 90024
Friends of Cancer Research
1800 M Street NW
Suite 1050 South
Washington, DC 22202
American Society of Clinical Oncology
2318 Mill Road Suite 800
Alexandria, VA 22314
Cancer Support Community
1050 17th St NW Suite 500
Washington, DC 20036
2201 E. Sixth Street
Austin, TX 78702
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email email@example.com
Last Updated: 3/20/2012
Copyright 1988, 1989, 1990, 1993, 1995, 1997, 1998, 2002, 2006, 2008, 2012 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.